Happy Monday, Cannabin-vestors! Roll out the green carpet. Barcelona takes center stage as host of the Cannabis Oscars!

Plus, the 20 most influential women in the cannabis industry and how to meet them in person in 2024.

Also, check out the newest episode of Cannabis Insider, also available on Apple and Spotify.*

Puff Pass: Did someone forward you this email? Click here to get automatically subscribed.

TOP STORY

The Rise Of Female Leadership In Cannabis: Top Executives Share Their Insights

Briefly: The cannabis industry is challenging norms in more ways than one.

So Basically: This dynamic sector, known for its rapid growth and evolving landscape, has become a platform for women leaders to innovate, inspire and advocate for a more equitable space.

So Then: Influential women across the cannabis spectrum shared their insights and experiences with Benzinga, highlighting the progress achieved and the challenges that persist.

So What? Their voices, pivotal in shaping the industry's future, emphasize the importance of female representation, empowerment and the ongoing efforts required to ensure women, particularly those of color, are no longer underrepresented or overlooked.

Click here to read more.

A MESSAGE FROM OUR PARTNERS

FIVE ZINGERS

Celebrate 4/20 with Method Man and Redman at BUD DROP concert in NYC

$400 million in cannabis industry deals will happen in just these 2 days, predicts CEO

Bullish sentiment across the cannabis space - Check full movers

Aurora exec says company well-positioned in Germany, will push for expansion of medical market

Cannabis isn't just masking symptoms — it can mend some underlying causes of disease, says mother, entrepreneur and activist

ONE FOR THE ROAD

Autism CBD Trial Enrolls Children

Briefly: SciSparc is testing its CBD drug for the treatment of children with ASD and has enrolled its first patient.

So Basically: The Israel-based companies said it will enroll 60 participants between the ages of 5 and 18, for 20 weeks.

So Then: The goal of the trial, which is designed in consultation with the National Autism Research Center, is to examine how SCI-210 therapy compares to standard CBD treatment in managing symptoms of ASD.

So What? "The enrollment of our first patient means that we are moving towards a new frontier in the treatment of ASD," said Oz Adler, the company's CEO.

Click here to read more.

A MESSAGE FROM OUR PARTNERS

KEEP READING

Before you go, be sure to subscribe to our other newsletters:

Ring The Bell: If you have to pick just one daily financial newsletter, it’s not a choice. Subscribe here.

The Street Sheet: A Wall Street cheat sheet, delivered every Sunday directly to your inbox. One-click subscribe here.

Future Finance: TradFi is tired. Wake up to the future of finance with this midday fintech and crypto letter. Subscribe here.

The Flag: Top takes from Washington to Wall Street impacting policy and your portfolio. One-click subscribe here.